Outcome of pediatric patients with lymphoma following stem cell transplant: a single institution report

References

• Donaldson SS, Link MP, Weinstein HJ, et al. Final results of a prospective clinical trial with VAMP and low-dose involved-field radiation for children with low-risk Hodgkin's disease. J Clin Oncol 2007;25:332–337.
   PubMed Web of Science ®Google Scholar
• Gerrard M, Cairo MS, Weston C, et al. Excellent survival following two courses of COPAD chemotherapy in children and adolescents with resected localized B-cell non-Hodgkin's lymphoma: results of the FAB/LMB 96 international study. Br J Haematol 2008;141:840–847.
   PubMed Web of Science ®Google Scholar
• Mauz-Korholz C, Hasenclever D, Dorffel W, et al. Procarbazine-free OEPA-COPDAC chemotherapy in boys and standard OPPA-COPP in girls have comparable effectiveness in pediatric Hodgkin's lymphoma: the GPOH-HD-2002 study. J Clin Oncol 2010;28:3680–3686.
   PubMed Web of Science ®Google Scholar
• Goldman S, Smith L, Anderson JR, et al. Rituximab and FAB/LMB 96 chemotherapy in children with stage III/IV B-cell non-Hodgkin lymphoma: a Children's Oncology Group report. Leukemia 2013;27:1174–1177.
   PubMed Web of Science ®Google Scholar
• Kelly KM, Sposto R, Hutchinson R, et al. BEACOPP chemotherapy is a highly effective regimen in children and adolescents with high-risk Hodgkin lymphoma: a report from the Children's Oncology Group. Blood 2011;117:2596–2603.
   PubMed Web of Science ®Google Scholar
• Reiter A, Schrappe M, Ludwig WD, et al. Intensive ALL-type therapy without local radiotherapy provides a 90% event-free survival for children with T-cell lymphoblastic lymphoma: a BFM group report. Blood 2000;95:416–421.
   PubMed Web of Science ®Google Scholar
• Belgaumi A, Al-Kofide AA, Jamil-Malik R, et al. Outcome of second line therapy for pediatric patients with Hodgkin lymphoma who relapse following ABVD-based therapy. Blood 2008;122(Suppl. 1): Abstract 1053.
   Google Scholar
• Gorde-Grosjean S, Oberlin O, Leblanc T, et al. Outcome of children and adolescents with recurrent/refractory classical Hodgkin lymphoma, a study from the Societe Francaise de Lutte contre le Cancer des Enfants et des Adolescents (SFCE). Br J Haematol 2012;158:649–656.
   PubMed Web of Science ®Google Scholar
• Schellong G, Dorffel W, Claviez A, et al. Salvage therapy of progressive and recurrent Hodgkin's disease: results from a multicenter study of the pediatric DAL/GPOH-HD study group. J Clin Oncol 2005;23:6181–6189.
   PubMed Web of Science ®Google Scholar
• Akhtar S, El Weshi A, Rahal M, et al. High-dose chemotherapy and autologous stem cell transplant in adolescent patients with relapsed or refractory Hodgkin's lymphoma. Bone Marrow Transplant 2010;45:476–482.
   PubMed Web of Science ®Google Scholar
• Harris RE, Termuhlen AM, Smith LM, et al. Autologous peripheral blood stem cell transplantation in children with refractory or relapsed lymphoma: results of Children's Oncology Group study A5962. Biol Blood Marrow Transplant 2011;17:249–258.
   PubMed Web of Science ®Google Scholar
• Shafer JA, Heslop HE, Brenner MK, et al. Outcome of hematopoietic stem cell transplant as salvage therapy for Hodgkin's lymphoma in adolescents and young adults at a single institution. Leuk Lymphoma 2010;51:664–670.
   PubMed Web of Science ®Google Scholar
• Bradley MB, Cairo MS. Stem cell transplantation for pediatric lymphoma: past, present and future. Bone Marrow Transplant 2008;41:149–158.
   PubMed Web of Science ®Google Scholar
• Giulino-Roth L, Ricafort R, Kernan NA, et al. Ten-year follow-up of pediatric patients with non-Hodgkin lymphoma treated with allogeneic or autologous stem cell transplantation. Pediatr Blood Cancer 2013;60:2018–2024.
   PubMed Web of Science ®Google Scholar
• Woessmann W, Zimmermann M, Lenhard M, et al. Relapsed or refractory anaplastic large-cell lymphoma in children and adolescents after Berlin-Frankfurt-Muenster (BFM)-type first-line therapy: a BFM-group study. J Clin Oncol 2011;29:3065–3071.
   PubMed Web of Science ®Google Scholar
• Metzger ML, Hudson MM, Krasin MJ, et al. Initial response to salvage therapy determines prognosis in relapsed pediatric Hodgkin lymphoma patients. Cancer 2010;116:4376–4384.
   PubMed Web of Science ®Google Scholar
• Harker-Murray PD, Drachtman RA, Hodgson DC, et al. Stratification of treatment intensity in relapsed pediatric Hodgkin lymphoma. Pediatr Blood Cancer 2014;61:579–586.
   PubMed Web of Science ®Google Scholar
• Stoneham S, Ashley S, Pinkerton CR, et al. Outcome after autologous hemopoietic stem cell transplantation in relapsed or refractory childhood Hodgkin disease. J Pediatr Hematol Oncol 2004;26:740–745.
   PubMed Web of Science ®Google Scholar
• Verdeguer A, Pardo N, Madero L, et al. Autologous stem cell transplantation for advanced Hodgkin's disease in children. Spanish group for BMT in children (GETMON), Spain. Bone Marrow Transplant 2000;25:31–34.
   PubMed Web of Science ®Google Scholar
• Won SC, Han JW, Kwon SY, et al. Autologous peripheral blood stem cell transplantation in children with non-Hodgkin's lymphoma: a report from the Korean society of pediatric hematology-oncology. Ann Hematol 2006;85:787–794.
   PubMed Web of Science ®Google Scholar
• Fujita N, Mori T, Mitsui T, et al. The role of hematopoietic stem cell transplantation with relapsed or primary refractory childhood B-cell non-Hodgkin lymphoma and mature B-cell leukemia: a retrospective analysis of enrolled cases in Japan. Pediatr Blood Cancer 2008;51:188–192.
   PubMed Web of Science ®Google Scholar
• Mitsui T, Mori T, Fujita N, et al. Retrospective analysis of relapsed or primary refractory childhood lymphoblastic lymphoma in Japan. Pediatr Blood Cancer 2009;52:591–595.
   PubMed Web of Science ®Google Scholar
• Kobrinsky NL, Sposto R, Shah NR, et al. Outcomes of treatment of children and adolescents with recurrent non-Hodgkin's lymphoma and Hodgkin's disease with dexamethasone, etoposide, cisplatin, cytarabine, and l-asparaginase, maintenance chemotherapy, and transplantation: Children's Cancer Group Study CCG-5912. J Clin Oncol 2001;19:2390–2396.
   PubMed Web of Science ®Google Scholar
• Burkhardt B, Reiter A, Landmann E, et al. Poor outcome for children and adolescents with progressive disease or relapse of lymphoblastic lymphoma: a report from the berlin-frankfurt-muenster group. J Clin Oncol 2009;27:3363–3369.
   PubMed Web of Science ®Google Scholar
• Gross TG, Hale GA, He W, et al. Hematopoietic stem cell transplantation for refractory or recurrent non-Hodgkin lymphoma in children and adolescents. Biol Blood Marrow Transplant 2010;16: 223–230.
   PubMed Web of Science ®Google Scholar
• Ladenstein R, Pearce R, Hartmann O, et al. High- dose chemotherapy with autologous bone marrow rescue in children with poor-risk Burkitt's lymphoma: a report from the European Lymphoma Bone Marrow Transplantation Registry. Blood 1997;90:2921–2930.
   PubMed Web of Science ®Google Scholar
• Woessmann W, Zimmermann M, Lenhard M, et al. Relapsed or refractory anaplastic large-cell lymphoma in children and adolescents after Berlin-Frankfurt-Muenster (BFM)–Type First-line therapy: a BFM-Group study. J Clin Oncol 2011;29:3065–3071.
   PubMed Web of Science ®Google Scholar
• Claviez A, Canals C, Dierickx D, et al. Allogeneic hematopoietic stem cell transplantation in children and adolescents with recurrent and refractory Hodgkin lymphoma: an analysis of the European Group for Blood and Marrow Transplantation. Blood 2009;114:2060–2067.
   PubMed Web of Science ®Google Scholar
• Satwani P, Jin Z, Martin PL, et al. Sequential myeloablative autologous stem cell transplantation and reduced intensity allogeneic hematopoietic cell transplantation is safe and feasible in children, adolescents and young adults with poor risk refractory or recurrent Hodgkin and non-Hodgkin lymphoma. Leukemia 2014 Jun 18. [Epub ahead of print]
   Google Scholar
• Sureda A, Canals C, Arranz R, et al. Allogeneic stem cell transplantation after reduced intensity conditioning in patients with relapsed or refractory Hodgkin's lymphoma. Results of the HDR-ALLO study - a prospective clinical trial by the Grupo Español de Linfomas/Trasplante de Médula Osea (GEL/TAMO) and the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Haematologica 2012;97:310–317.
   PubMed Web of Science ®Google Scholar
• Bacher U. Conditioning regimens for allotransplants for diffuse large B-cell lymphoma: myeloablative or reduced intensity? Blood 2012;120:4256–4262.
   PubMed Web of Science ®Google Scholar
• Hamadani M, Saber W, Ahn KW, et al. Impact of pretransplantation conditioning regimens on outcomes of allogeneic transplantation for chemotherapy-unresponsive diffuse large B cell lymphoma and grade III follicular lymphoma. Biol Blood Marrow Transplant 2013;19:746–753.
   PubMed Web of Science ®Google Scholar
• Tse E, Kwong YL. How I treat NK/T-cell lymphomas. Blood 2013;121:4997–5005.
   PubMed Web of Science ®Google Scholar
• Kwong YL. The diagnosis and management of extranodal NK/ T-cell lymphoma, nasal-type and aggressive NK-cell leukemia. J Clin Exp Hematop 2011;51:21–28.
   PubMedGoogle Scholar
• Kim HJ, Bang SM, Lee J, et al. High-dose chemotherapy with autologous stem cell transplantation in extranodal NK/T-cell lymphoma: a retrospective comparison with non-transplantation cases. Bone Marrow Transplant 2006;37:819–824.
   PubMed Web of Science ®Google Scholar